Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Funds Are Buying Ironwood Pharmaceuticals, Inc. (IRWD)

Page 1 of 2

At Insider Monkey we track the activity of some of the best-performing hedge funds like Appaloosa Management, Baupost, and Third Point because we determined that some of the stocks that they are collectively bullish on can help us generate returns above the broader indices. Out of thousands of stocks that hedge funds invest in, small-caps can provide the best returns over the long term due to the fact that these companies are less efficiently priced and are usually under the radars of mass-media, analysts and dumb money. This is why we follow the smart money moves in the small-cap space.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) shareholders have witnessed an increase in activity from the world’s largest hedge funds lately. IRWD was in 21 hedge funds’ portfolios at the end of September. There were 18 hedge funds in our database with IRWD holdings at the end of the previous quarter. At the end of this article we will also compare IRWD to other stocks including Finisar Corporation (NASDAQ:FNSR), KBR, Inc. (NYSE:KBR), and Groupon Inc (NASDAQ:GRPN) to get a better sense of its popularity.

Follow Ironwood Pharmaceuticals Inc (NASDAQ:IRWD)
Trade (NASDAQ:IRWD) Now!

At Insider Monkey, we’ve developed an investment strategy that has delivered market-beating returns over the past 12 months. Our strategy identifies the 100 best-performing funds of the previous quarter from among the collection of 700+ successful funds that we track in our database, which we accomplish using our returns methodology. We then study the portfolios of those 100 funds using the latest 13F data to uncover the 30 most popular mid-cap stocks (market caps of between $1 billion and $10 billion) among them to hold until the next filing period. This strategy delivered 18% gains over the past 12 months, more than doubling the 8% returns enjoyed by the S&P 500 ETFs.

bogdanhoda/Shutterstock.com

bogdanhoda/Shutterstock.com

What have hedge funds been doing with Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)?

Heading into the fourth quarter of 2016, a total of 21 of the hedge funds tracked by Insider Monkey held long positions in this stock, a 17% bump from the second quarter of 2016, with ownership of the stock among hedge funds rising to a yearly high as a result. With hedgies’ capital changing hands, there exists an “upper tier” of notable hedge fund managers who were boosting their holdings significantly (or already accumulated large positions).

HedgeFundSentimentChart

When looking at the institutional investors followed by Insider Monkey, OrbiMed Advisors, managed by Samuel Isaly, holds the most valuable position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). OrbiMed Advisors has a $158 million position in the stock, comprising 1.8% of its 13F portfolio. The second most bullish fund manager is Adage Capital Management, managed by Phill Gross and Robert Atchinson, which holds an $86.1 million position. Some other hedge funds and institutional investors with similar optimism comprise Roberto Mignone’s Bridger Management, Mitchell Blutt’s Consonance Capital Management and Oleg Nodelman’s EcoR1 Capital.

Page 1 of 2
Loading Comments...